Trial Outcomes & Findings for Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia (NCT NCT04541186)

NCT ID: NCT04541186

Last Updated: 2024-07-25

Results Overview

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 86 participants
• Primary outcome timeframe: Baseline, Week 8
• Results posted on: 2024-07-25

Participant Flow

As per the Statistical Analysis Plan (SAP), since a low number of participants enrolled in the fibrate cohort (3 on placebo and 3 on active treatment [pegozafermin]), participants in the pegozafermin 27 mg QW fibrate cohort were combined with the pegozafermin 27 mg QW main cohort, forming a pooled pegozafermin 27 mg QW group for analyses. Similarly, the placebo participants in the fibrate cohort were combined with the main placebo group (pooled) for analyses.

Participant milestones

Measure	Pegozafermin 9 mg QW Pegozafermin 9 mg QW was administered as a subcutaneous (SC) injection.	Pegozafermin 18 mg QW Pegozafermin 18 mg QW was administered as an SC injection.	Pegozafermin 27 mg QW Pegozafermin 27 mg QW was administered as an SC injection.	Pegozafermin 36 mg Q2W Pegozafermin 36 mg Q2W was administered as an SC injection.	Placebo Matching placebo was injected at matching frequency per assigned cohort.
Main Study STARTED	16	17	16	16	15
Main Study Safety Analysis Set	12	21	15	16	15
Main Study Full Analysis Set (FAS)	16	17	13	16	14
Main Study COMPLETED	15	16	10	15	14
Main Study NOT COMPLETED	1	1	6	1	1
Fibrate Expansion Study STARTED	0	0	3	0	3
Fibrate Expansion Study Received at Least 1 Dose of Study Drug	0	0	3	0	3
Fibrate Expansion Study Full Analysis Set	0	0	3	0	3
Fibrate Expansion Study COMPLETED	0	0	3	0	2
Fibrate Expansion Study NOT COMPLETED	0	0	0	0	1

Reasons for withdrawal

Measure	Pegozafermin 9 mg QW Pegozafermin 9 mg QW was administered as a subcutaneous (SC) injection.	Pegozafermin 18 mg QW Pegozafermin 18 mg QW was administered as an SC injection.	Pegozafermin 27 mg QW Pegozafermin 27 mg QW was administered as an SC injection.	Pegozafermin 36 mg Q2W Pegozafermin 36 mg Q2W was administered as an SC injection.	Placebo Matching placebo was injected at matching frequency per assigned cohort.
Main Study Adverse Event	0	0	4	0	0
Main Study Investigator Decision	0	0	1	1	0
Main Study Withdrawal by Subject	1	1	0	0	0
Main Study COVID-19-related Dose Interruption	0	0	0	0	1
Main Study Randomized in Error Not Treated	0	0	1	0	0
Fibrate Expansion Study Other than Specified	0	0	0	0	1

Baseline Characteristics

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

Baseline characteristics by cohort

Measure	Pegozafermin 9 mg QW n=12 Participants Pegozafermin 9 mg QW was administered as a SC injection.	Pegozafermin 18 mg QW n=21 Participants Pegozafermin 18 mg QW was administered as an SC injection.	Pegozafermin 27 mg QW n=18 Participants Pegozafermin 27 mg QW was administered as an SC injection. The Main Study cohort and Fibrate Expansion cohort for pegozafermin 27 mg were pooled together due to low sample size in the expansion cohort.	Pegozafermin 36 mg Q2W n=16 Participants Pegozafermin 36 mg Q2W was administered as an SC injection.	Placebo n=18 Participants Matching placebo was injected at matching frequency per assigned cohort. Main Study cohort and Fibrate Expansion cohort for placebo were pooled together due to low sample size in the expansion cohort.	Total n=85 Participants Total of all reporting groups
Age, Continuous	52.8 years STANDARD_DEVIATION 14.12 • n=5 Participants	51.3 years STANDARD_DEVIATION 10.81 • n=7 Participants	53.9 years STANDARD_DEVIATION 7.18 • n=5 Participants	53.1 years STANDARD_DEVIATION 12.36 • n=4 Participants	57.5 years STANDARD_DEVIATION 10.30 • n=21 Participants	53.7 years STANDARD_DEVIATION 10.86 • n=8 Participants
Sex: Female, Male Female	4 Participants n=5 Participants	4 Participants n=7 Participants	5 Participants n=5 Participants	2 Participants n=4 Participants	6 Participants n=21 Participants	21 Participants n=8 Participants
Sex: Female, Male Male	8 Participants n=5 Participants	17 Participants n=7 Participants	13 Participants n=5 Participants	14 Participants n=4 Participants	12 Participants n=21 Participants	64 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	3 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants	5 Participants n=4 Participants	3 Participants n=21 Participants	17 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	9 Participants n=5 Participants	19 Participants n=7 Participants	14 Participants n=5 Participants	11 Participants n=4 Participants	15 Participants n=21 Participants	68 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race/Ethnicity, Customized Race · Black	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	2 Participants n=8 Participants
Race/Ethnicity, Customized Race · White	11 Participants n=5 Participants	21 Participants n=7 Participants	18 Participants n=5 Participants	14 Participants n=4 Participants	17 Participants n=21 Participants	81 Participants n=8 Participants
Race/Ethnicity, Customized Race · Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race/Ethnicity, Customized Race · Unknown	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Triglyceride (TG) Level <750 mg/dL	9 Participants n=5 Participants	14 Participants n=7 Participants	12 Participants n=5 Participants	9 Participants n=4 Participants	13 Participants n=21 Participants	57 Participants n=8 Participants
Triglyceride (TG) Level ≥750 mg/dL	3 Participants n=5 Participants	7 Participants n=7 Participants	6 Participants n=5 Participants	7 Participants n=4 Participants	5 Participants n=21 Participants	28 Participants n=8 Participants

PRIMARY outcome

Timeframe: Baseline, Week 8

Population: FAS: Participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline TG measurement not including EOS visit. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. As pre-specified in the SAP, the sample size in each arm (by dose group) was insufficient (under powered) to effectively evaluate differences in efficacy by dose, therefore, efficacy analysis was performed using total pegozafermin and placebo groups.

Outcome measures

Measure	Pegozafermin n=64 Participants All participants who were randomized to pegozafermin in the main study and fibrate expansion cohort were pooled together.	Placebo n=17 Participants Participants randomized to placebo in the main study and fibrate expansion cohort were pooled together.
Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)	-57.33 percent change from Baseline Interval -69.07 to -32.31	-11.85 percent change from Baseline Interval -23.22 to 7.88

SECONDARY outcome

Timeframe: Week 8

Population: FAS: Participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline TG measurement not including EOS visit. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. As pre-specified in the SAP, the sample size in each arm (by dose group) was insufficient (under powered) to effectively evaluate differences in efficacy by dose, therefore, efficacy analysis was performed using total pegozafermin and placebo groups.

Outcome measures

Measure	Pegozafermin n=64 Participants All participants who were randomized to pegozafermin in the main study and fibrate expansion cohort were pooled together.	Placebo n=17 Participants Participants randomized to placebo in the main study and fibrate expansion cohort were pooled together.
Number of Participants Who Achieved TG <500 mg/dL at Week 8	51 Participants	5 Participants

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: FAS: Participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline TG measurement not including EOS visit. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. As pre-specified in the SAP, the sample size in each arm (by dose group) was insufficient (under powered) to effectively evaluate differences in efficacy by dose, therefore, efficacy analysis was performed using total pegozafermin and placebo groups.

Least Squares Means were calculated using mixed-model repeated measures (MMRM).

Outcome measures

Measure	Pegozafermin n=63 Participants All participants who were randomized to pegozafermin in the main study and fibrate expansion cohort were pooled together.	Placebo n=17 Participants Participants randomized to placebo in the main study and fibrate expansion cohort were pooled together.
Percent Change From Baseline to Week 8 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B100 (ApoB), Low-density Lipoprotein Cholesterol (LDL-C), and High-density Lipoprotein Cholesterol (HDL-C) Non-HDL-C	-18.29 percent change from Baseline Standard Error 2.943	-0.57 percent change from Baseline Standard Error 5.586
Percent Change From Baseline to Week 8 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B100 (ApoB), Low-density Lipoprotein Cholesterol (LDL-C), and High-density Lipoprotein Cholesterol (HDL-C) ApoB	-10.51 percent change from Baseline Standard Error 2.238	1.07 percent change from Baseline Standard Error 4.309
Percent Change From Baseline to Week 8 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B100 (ApoB), Low-density Lipoprotein Cholesterol (LDL-C), and High-density Lipoprotein Cholesterol (HDL-C) LDL-C	10.44 percent change from Baseline Standard Error 4.654	8.72 percent change from Baseline Standard Error 9.018
Percent Change From Baseline to Week 8 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B100 (ApoB), Low-density Lipoprotein Cholesterol (LDL-C), and High-density Lipoprotein Cholesterol (HDL-C) HDL-C	24.65 percent change from Baseline Standard Error 3.752	9.67 percent change from Baseline Standard Error 7.045

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: FAS: Participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline TG measurement not including EOS visit. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. As pre-specified in the SAP, the sample size in each arm (by dose group) was insufficient (under powered) to effectively evaluate differences in efficacy by dose, therefore, efficacy analysis was performed using total pegozafermin and placebo groups.

Outcome measures

Measure	Pegozafermin n=62 Participants All participants who were randomized to pegozafermin in the main study and fibrate expansion cohort were pooled together.	Placebo n=15 Participants Participants randomized to placebo in the main study and fibrate expansion cohort were pooled together.
Percent Change From Baseline to Week 8 in Very Low-density Lipoprotein Cholesterol (VLDL-C) and VLDL-TG VLDL-C	-47.96 percent change from Baseline Interval -63.14 to -16.67	-0.41 percent change from Baseline Interval -30.38 to 10.98
Percent Change From Baseline to Week 8 in Very Low-density Lipoprotein Cholesterol (VLDL-C) and VLDL-TG VLDL-TG	-58.50 percent change from Baseline Interval -72.53 to -32.8	-0.85 percent change from Baseline Interval -27.72 to 14.25

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: FAS: Participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline TG measurement not including EOS visit. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. As pre-specified in the SAP, the sample size in each arm (by dose group) was insufficient (under powered) to effectively evaluate differences in efficacy by dose, therefore, efficacy analysis was performed using total pegozafermin and placebo groups.

Least Squares Mean was calculated using MMRM.

Outcome measures

Measure	Pegozafermin n=63 Participants All participants who were randomized to pegozafermin in the main study and fibrate expansion cohort were pooled together.	Placebo n=17 Participants Participants randomized to placebo in the main study and fibrate expansion cohort were pooled together.
Percent Change in Baseline to Week 8 in Fasting Plasma Glucose, Adiponectin, and Body Weight Fasting Plasma Glucose	-3.90 percent change from Baseline Standard Error 2.681	-2.67 percent change from Baseline Standard Error 5.230
Percent Change in Baseline to Week 8 in Fasting Plasma Glucose, Adiponectin, and Body Weight Adiponectin	69.53 percent change from Baseline Standard Error 7.383	5.70 percent change from Baseline Standard Error 14.556
Percent Change in Baseline to Week 8 in Fasting Plasma Glucose, Adiponectin, and Body Weight Body Weight	-0.15 percent change from Baseline Standard Error 0.339	-0.14 percent change from Baseline Standard Error 0.654

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: All participants in the FAS who had baseline and a follow-up MRI-PDFF assessment. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. As pre-specified in the SAP, the sample size in each arm (by dose group) was insufficient (under powered) to effectively evaluate differences in efficacy by dose, therefore, efficacy analysis was performed using total pegozafermin and placebo groups.

Least Squares Mean was calculated using analysis of covariance (ANCOVA).

Outcome measures

Measure	Pegozafermin n=17 Participants All participants who were randomized to pegozafermin in the main study and fibrate expansion cohort were pooled together.	Placebo n=6 Participants Participants randomized to placebo in the main study and fibrate expansion cohort were pooled together.
Percent Change From Baseline to Week 8 in Liver Fat as Assessed by Magnetic Resonance Imaging - Whole Liver Proton Density Fat Fraction (MRI-PDFF)	-42.18 percent change from Baseline Standard Error 6.207	-8.26 percent change from Baseline Standard Error 11.214

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: FAS: Participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline TG measurement not including EOS visit. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. As pre-specified in the SAP, the sample size in each arm (by dose group) was insufficient (under powered) to effectively evaluate differences in efficacy by dose, therefore, efficacy analysis was performed using total pegozafermin and placebo groups.

Outcome measures

Measure	Pegozafermin n=63 Participants All participants who were randomized to pegozafermin in the main study and fibrate expansion cohort were pooled together.	Placebo n=17 Participants Participants randomized to placebo in the main study and fibrate expansion cohort were pooled together.
Percent Change From Baseline to Week 8 in High-sensitivity C-reactive Protein (hsCRP)	-21.43 percent change from Baseline Interval -43.3 to 42.37	-1.10 percent change from Baseline Interval -50.41 to 18.84

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: FAS: Participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline TG measurement not including EOS visit. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. As pre-specified in the SAP, the sample size in each arm (by dose group) was insufficient (under powered) to effectively evaluate differences in efficacy by dose, therefore, efficacy analysis was performed using total pegozafermin and placebo groups.

Least Squares Mean was calculated using MMRM.

Outcome measures

Measure	Pegozafermin n=63 Participants All participants who were randomized to pegozafermin in the main study and fibrate expansion cohort were pooled together.	Placebo n=17 Participants Participants randomized to placebo in the main study and fibrate expansion cohort were pooled together.
Percent Change From Baseline to Week 8 in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ALT	-4.28 percent change from Baseline Standard Error 4.549	0.43 percent change from Baseline Standard Error 8.881
Percent Change From Baseline to Week 8 in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) AST	-11.50 percent change from Baseline Standard Error 3.341	0.51 percent change from Baseline Standard Error 6.597

Adverse Events

Pegozafermin 9 mg QW

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

Pegozafermin 18 mg QW

Serious events: 0 serious events

Other events: 13 other events

Deaths: 0 deaths

Pegozafermin 27 mg QW

Serious events: 1 serious events

Other events: 13 other events

Deaths: 0 deaths

Pegozafermin 36 mg Q2W

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

Placebo

Serious events: 0 serious events

Other events: 9 other events

Deaths: 0 deaths

Serious adverse events

Measure	Pegozafermin 9 mg QW n=12 participants at risk Pegozafermin 9 mg QW was administered as a SC injection.	Pegozafermin 18 mg QW n=21 participants at risk Pegozafermin 18 mg QW was administered as an SC injection.	Pegozafermin 27 mg QW n=18 participants at risk Pegozafermin 27 mg QW was administered as an SC injection. The Main Study cohort and Fibrate Expansion cohort for pegozafermin 27 mg were pooled together due to low sample size in the expansion cohort.	Pegozafermin 36 mg Q2W n=16 participants at risk Pegozafermin 36 mg Q2W was administered as an SC injection.	Placebo n=18 participants at risk Matching placebo was injected at matching frequency per assigned cohort. Main Study cohort and Fibrate Expansion cohort for placebo were pooled together due to low sample size in the expansion cohort.
Vascular disorders Hypertension	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.

Other adverse events

Measure	Pegozafermin 9 mg QW n=12 participants at risk Pegozafermin 9 mg QW was administered as a SC injection.	Pegozafermin 18 mg QW n=21 participants at risk Pegozafermin 18 mg QW was administered as an SC injection.	Pegozafermin 27 mg QW n=18 participants at risk Pegozafermin 27 mg QW was administered as an SC injection. The Main Study cohort and Fibrate Expansion cohort for pegozafermin 27 mg were pooled together due to low sample size in the expansion cohort.	Pegozafermin 36 mg Q2W n=16 participants at risk Pegozafermin 36 mg Q2W was administered as an SC injection.	Placebo n=18 participants at risk Matching placebo was injected at matching frequency per assigned cohort. Main Study cohort and Fibrate Expansion cohort for placebo were pooled together due to low sample size in the expansion cohort.
Endocrine disorders Hyperthyroidism	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Cardiac disorders Atrioventricular block first degree	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Cardiac disorders Supraventricular extrasystoles	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
General disorders Injection site reaction	8.3% 1/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	9.5% 2/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	12.5% 2/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
General disorders Injection site erythema	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	4.8% 1/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	11.1% 2/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
General disorders Injection site pruritus	8.3% 1/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	9.5% 2/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Infections and infestations COVID-19	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	14.3% 3/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	16.7% 3/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Blood and lymphatic system disorders Anaemia	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Blood and lymphatic system disorders Lymphadenitis	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Gastrointestinal disorders Abdominal pain	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	11.1% 2/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Gastrointestinal disorders Diarrhoea	16.7% 2/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	4.8% 1/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	22.2% 4/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Gastrointestinal disorders Diverticulum	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Gastrointestinal disorders Frequent bowel movements	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	4.8% 1/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Gastrointestinal disorders Inguinal hernia	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Gastrointestinal disorders Nausea	8.3% 1/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	4.8% 1/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	27.8% 5/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	12.5% 2/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Gastrointestinal disorders Vomiting	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
General disorders Fatigue	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	11.1% 2/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
General disorders Injection site bruising	8.3% 1/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
General disorders Injection site induration	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
General disorders Injection site pain	8.3% 1/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
General disorders Pyrexia	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Hepatobiliary disorders Hepatic steatosis	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Infections and infestations Gastroenteritis	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Infections and infestations Otitis media	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	4.8% 1/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Infections and infestations Respiratory tract infection viral	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Infections and infestations Sinusitis	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Infections and infestations Urinary tract infection	8.3% 1/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Infections and infestations Viral upper respiratory tract infection	8.3% 1/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Injury, poisoning and procedural complications Contusion	8.3% 1/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Injury, poisoning and procedural complications Corneal abrasion	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Injury, poisoning and procedural complications Skin laceration	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Investigations Blood creatine phosphokinase increased	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Investigations Blood thyroid stimulating hormone increased	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Investigations C-reactive protein increased	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Metabolism and nutrition disorders Increased appetite	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	4.8% 1/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	11.1% 2/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Nervous system disorders Dizziness	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Nervous system disorders Dysgeusia	8.3% 1/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Nervous system disorders Headache	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	11.1% 2/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Nervous system disorders Paraesthesia	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Nervous system disorders Taste disorder	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	4.8% 1/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Skin and subcutaneous tissue disorders Dermatitis contact	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Skin and subcutaneous tissue disorders Ecchymosis	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Skin and subcutaneous tissue disorders Pigmentation disorder	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Vascular disorders Hypertension	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	6.2% 1/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.
Vascular disorders Lymphoedema	0.00% 0/12 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/21 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	0.00% 0/16 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.	5.6% 1/18 • Day 1 (after dosing) up to 12 weeks As per the SAP, since a low number of participants enrolled in the fibrate cohort, participants in the pegozafermin 27 mg QW fibrate cohort were pooled with the pegozafermin 27 mg QW main cohort. Similarly, placebo groups in main and fibrate cohorts were pooled. Safety Analysis Set: Participants who received at least 1 dose of study drug. Safety data analysis was by treatment group received. 4 participants randomized to receive 9 mg QW received 18 mg QW instead.

Additional Information

Entrigue Study Team

89bio, Inc.

Phone: 1-415-432-9270

Email: Ct.gov_SHTG@89bio.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place